Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / New Drug Can Protect High-Risk Heart Patients - The Issue Is...

March 30, 2017

New Drug Can Protect High-Risk Heart Patients – The Issue Is Cost

An expensive new drug that radically lowers cholesterol levels has proven to also significantly reduce the chances of a heart attack or stroke in high risk patients. This is according to the results of a study recently published in The New England Journal of Medicine. Amgen, the maker of the drug, Repatha, paid for the nearly $1 billion study and hoped to legitimize their expectation that the drug would do more than just lower the levels of LDL cholesterol – and it was proven. According to this New York Times article, Dr. Eugene Braunwald, a cardiologist at Harvard Medical School, believes that this new class of drugs have the potential to “improve the health and longevity of millions of Americans with heart disease.” Considering heart disease is the leading cause of death among Americans, this is very good news. However, the challenge here is cost. These new drugs have a list price of $14,523 a year. Check out the article to learn more about this financial barrier and the reluctance of insurance companies to pay for this class of drugs before the new data was released.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2023 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap